Area of research
Psychiatry and Mental health · Pharmacology
Research interest
Research interests include Schizophrenia research and treatment, Treatment of Major Depression, Tryptophan and brain disorders, and Mental Health and Psychiatry.
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia
The history and geographic distribution of a KCNQ1 atrial fibrillation risk allele
Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression
Efficient Precision Genome Editing in iPSCs via Genetic Co-targeting with Selection
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
Critical Role for Telomerase in the Mechanism of Flow-Mediated Dilation in the Human Microcirculation
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
A near-infrared fluorescent voltage-sensitive dye allows for moderate-throughput electrophysiological analyses of human induced pluripotent stem cell-derived cardiomyocytes
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?
Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations
Interference control in adult ADHD: No evidence for interference control deficits if response speed is controlled by delta plots
Maturation of Human Embryonic Stem Cell–Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice
Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia
Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans
Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale
Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder
Response trajectories in “real-world” naturalistically treated schizophrenia patients